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Abstract Respiratory syncytial virus (RSV) infection up-regu-
lates the expression of genes encoding proin£ammatory media-
tors in bronchial epithelial cells. However, the speci¢c signaling
events immediately following RSV exposure are poorly under-
stood. Herein, we report that RSV attachment to A549 cells
activates both ERK-1 and ERK-2 pathways within 5 min. Inhi-
bition of ERK pathways signi¢cantly decreases RSV infection
of these cells compared to controls. These results demonstrate
that the activation of the ERK-1/2 is required in RSV-induced
early gene expression.
. 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The development of novel therapies against infection by
respiratory syncytial virus (RSV) is a global priority. A typi-
cally short incubation period of 1^2 days and the need
to induce protective immunity in infants within the ¢rst
2 months of life is a major impediment to the development
of e¡ective vaccines against RSV infection [1^3]. Developing
an antiviral prophylaxis requires a comprehensive molecular
understanding of the early events of infection. In cultured
epithelial cells and in the murine model, RSV infection up-
regulates the expression of several cytokines and chemokines
such as interleukin (IL)-1L, IL-6, IL-8, tumor necrosis factor-
K, macrophage in£ammatory protein-1K, RANTES, interfer-
on-L, and intercellular adhesion molecule-1, which contribute
to the acute in£ammation [4^6]. Activation of transcription
factors such as the nuclear factor-UB (NF-UB) and signal
transducers and activators of transcription (STATs) is re-
quired for the expression of these in£ammatory molecules in
RSV-infected cells [7^14].
Based on the transfac promoter analysis of RSV-induced
early genes identi¢ed in microarray studies, we postulated
that RSV activates multiple signaling pathways in epithelial
cells [15,16]. This analysis revealed binding sites for activator
protein-1 suggesting that extracellular signal-regulated kinases
(ERKs) may also be involved in early gene expression. ERK-1
and ERK-2 mediate speci¢c responses to diverse stimuli, in-
cluding viruses, cytokines, and growth factors and hormones
[17^21]. RSV-induced production of IL-8 and RANTES is
dependent on activated ERK-2 [22,23]. However, the role of
ERKs in early signaling responses in RSV infection remains
poorly understood. Also, whether interrupting ERK pathways
can alter the course of viral infection is not known.
In this study, the results demonstrate that both ERK-1 and
ERK-2 are rapidly activated in A549 cells upon RSV expo-
sure and that ERK-1/2 activation is required for a successful
RSV replication.
2. Materials and methods
2.1. Virus strains and cell culture
RSV A2 strain was obtained from the American Type Culture
Collection (ATCC, Rockville, MD, USA). In some experiments,
rgRSV (an engineered RSV expressing enhanced green £uorescent
protein) was used. A549 cell line, representing type II alveolar epithe-
lial cells, was obtained from the ATCC. The cells were grown at 37‡C
in 5% CO2 in RPMI medium, supplemented with 10% fetal bovine
serum. Normal human bronchial epithelial cells (NHBE) were ob-
tained from Cambrex (Walkersville, MD, USA) and grown in se-
rum-free bronchial epithelium growth medium supplemented as indi-
cated by the manufacturer. NHBE at passage 2 and 3 was used for the
experiments.
2.2. Reagents
Heparin and heparinase were obtained from Sigma-Aldrich (St.
Louis, MO, USA). AG490 (Janus kinase (JAK) inhibitor), PD98059
(MAPK/ERK kinase-1 (MEK-1) inhibitor), were obtained from Cal-
biochem (San Diego, CA, USA). Polyclonal anti-phospho antibodies
or antibodies to STAT-1, ERK, or IUBK were obtained from Cell
Signaling (Beverly, MA, USA). Fluorescein isothiocyanate (FITC)-
labeled anti-RSV N mouse monoclonal antibody was obtained from
Chemicon (Temecula, CA, USA).
2.3. Treatment with inhibitors
A549 cells were incubated with AG490 (50 WM) or PD98059 (80
WM) for 4 h at 37‡C and then infected with RSV. At 30 min, 60 min,
and 240 min following infection, the cells were washed with phos-
phate-bu¡ered saline (PBS) and the total protein extracted (see Sec-
tion 2.7). In some experiments, subcon£uent NHBE cells were ex-
posed to AG490 (50 WM) and PD98059 (80 WM) for 2 h at 37‡C
prior to rgRSV infection.
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2.4. Heparin and heparinase treatment
Either A549 cells or RSV was incubated with 1000 U/ml heparin at
37‡C for 2 h before proceeding to infection for 30 min at 37‡C. After
treatment, the cells were washed with PBS and total protein was
extracted. In some experiments, heparinase (10 U/ml) was used fol-
lowing the same protocol explained above.
2.5. RSV puri¢cation and plaque assay
RSV was PEG-precipitated and puri¢ed on two successive sucrose
density gradients as described [16]. Plaque assay was used to deter-
mine infectious viral titers of puri¢ed fractions, as described [14,16].
Because of the possible contamination of ATCC RSV with human
adenovirus type 1, we tested our puri¢ed preparations for the presence
of adenovirus by polymerase chain reaction using speci¢c primers that
amplify a product of 213 bp and previously reported by Cameron et
al. [24] and found that our preparations were not contaminated with
adenovirus.
2.6. Immuno£uorescence
Acetone-¢xed cells were stained with FITC-labeled anti-RSV mono-
clonal antibodies, as described [16]. RSV positive cells (green £uores-
cence) were counted randomly from 15 di¡erent spots and from two
or three di¡erent slides for each treatment group and the percentages
of infected cells were plotted for wild type (WT) and dominant neg-
ative (DN) mutant cells.
2.7. Immunoblotting
Whole cell protein extracts were prepared by lysing cells in 50 mM
HEPES, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol,
0.5% NP-40, 0.1 mM phenylmethylsulfonyl £uoride, 2.5 Wg/ml leupep-
tin, 0.5 mM NaF, and 0.1 mM sodium vanadate. 50 Wg whole cell
protein was subjected to sodium dodecyl sulfate^polyacrylamide gel
electrophoresis (SDS^PAGE) in 10% polyacrylamide and then trans-
ferred onto a nitrocellulose membrane, which was processed following
the (insert) manufacturers’ instructions. The antibody reactions were
detected by enhanced chemiluminescence using Lumiglo (Cell Signal-
ing Technology).
2.8. Mitogen-activated protein (MAP) kinase assay
A549 cells were infected with puri¢ed RSV and harvested at various
times post infection, as speci¢ed. ERK-1/2 were immunoprecipitated
and their kinase activity was tested using an Elk-1 fusion protein (Cell
Signaling Technology, Beverly, MA, USA). Elk-1 phosphorylation at
Ser383 was determined by Western blot.
2.9. DNA transfection
WT and DN mutant MEK-1 has been described previously [25]. In
addition, plasmid DNA of WT and mutant STAT-1K was also used in
other experiments. A549 cells grown in a 100 mm tissue culture plate
to 70^80% con£uence were transfected with 12 Wg of DNA and 35 Wl
of Lipofectin (Life Technology) for 15 h at 37‡C following the guide-
lines of the instruction manual. Cells were then infected with RSV for
30 min at 37‡C before cell protein was extracted.
2.10. Statistical analysis
Statistical signi¢cance was analyzed using Student’s t-test for paired
observations. A P6 0.05 level of signi¢cance (two-sided) was utilized
throughout.
3. Results
3.1. RSV exposure induces ERK-1 and ERK-2 phosphorylation
in A549 epithelial cells
RSV infection induced the increased phosphorylation of
ERK-1 and ERK-2 in A549 cells, as demonstrated by West-
ern blotting using corresponding antibodies and phospho-
antibodies (Fig. 1A). The phosphorylation of the ERK-1
and ERK-2 was induced at 5 min post RSV exposure and
continued until 2 h post RSV infection. At 4 h following
exposure to RSV, ERK-1 and ERK-2 phosphorylation was
not detected; however, ERK-1 and ERK-2 phosphorylation
reappeared at 24 h after infection. Assays of A549 cells in-
fected with sucrose-puri¢ed RSV at a multiplicity of infection
of 1 con¢rmed that the rapid activation of ERK-1/2 is due to
RSV per se and not to cytokines or growth factors (Fig. 1B).
The rapid activation of ERK-1/2 suggested that RSV attach-
ment is responsible for triggering the signaling. In fact, hep-
arin, a known inhibitor of RSV attachment [26,27], abolished
the RSV-induced activation of ERK-1/2 (Fig. 2).
3.2. ERK-1/2 phosphorylation is linked with activation of
STAT-1K and of IUB
A549 cells exhibit activation of STAT-1K and STAT-3 and
NF-UB following exposure to RSV [16]. Speci¢c inhibitors to
STAT-1K and ERK-1/2 pathways were used to determine if
blocking one pathway a¡ects the phosphorylation of both of
them and IUBK (Fig. 3A,B). A decrease in RSV-induced
STAT-1K phosphorylation and in IUBK phosphorylation in
cells pre-incubated with AG490 suggests a possible interaction
between these two pathways. Although AG490 failed to in-
hibit ERK activation, PD98059 signi¢cantly a¡ected the
Fig. 1. Exposure to RSV activates ERK-1 and ERK-2 in A549 cells.
A: RSV exposure induces rapid phosphorylation of ERK-1/2 in
A549 cells. Western blots of total proteins extracted from uninfected
cells and RSV-infected cells for 5, 10, 15 or 30 min and for 1, 4, or
24 h probed with anti-phospho ERK-1/2, stripped, and then re-
probed with anti-ERK-1/2. B: Activity assay of ERK-1/2 immuno-
precipitated from 200 Wg of total proteins extracted from uninfected
cells and sucrose-puri¢ed RSV-infected cells.
Fig. 2. E¡ect of heparin and heparinase on RSV-induced ERK-1/2
activation. Proteins were isolated from untreated cells (lane 1) or
cells infected with RSV for 30 min (lanes 2^6) after pretreatment of
cells for 30 min with heparinase (lane 3) or heparin (lane 5), or in-
fected with virus pretreated with heparinase (lane 4) or heparin
(lane 6) prior to addition to the cells. Proteins were separated by
SDS^PAGE, blotted and probed with anti-phospho ERK-1/2 and
then reprobed with anti-ERK-1/2.
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phosphorylation of both STAT-1K and IUB (Fig. 3B). To
determine if phospho-STAT-1K is required for the increase
in phospho-ERK-1/2 seen in RSV infection, cells were trans-
fected with plasmids encoding either WT- or DN-STAT-1K.
Both STAT-1K and ERK-1/2 phosphorylation decreased in
cells transfected with DN STAT-1K compared to WT
STAT-1K in response to RSV infection (Fig. 3C). Together,
these results suggest that both STAT-1K and ERK-1/2 partic-
ipate in the phosphorylation of each other as well as in phos-
phorylation of IUBK in the context of RSV infection.
3.3. Inhibition of ERKs attenuates RSV infection
To examine whether ERKs play a speci¢c role in RSV in-
fection, A549 cells were treated with PD98059 and then in-
fected with RSV. After 24 h of RSV infection, there was a
decrease in the percentage of infected cells treated with the
inhibitor compared to those treated with control, suggesting
that the ERK pathway plays a role during RSV infection (Fig.
4A). Moreover, the number of infected cells in DN MEK-1-
transfected A549 cells was reduced in s 60% compared to
those transfected with a WT construct (Fig. 4B). These results
Fig. 3. E¡ects of inhibitors of phosphorylation of STAT-1K and ERK-1/2. A: AG490- or PD98059-treated A549 cells were infected with RSV
for 15 min. Total proteins were Western-blotted using speci¢c anti-phospho antibodies to STAT-1K, ERK-1/2 or IUBK. Lane 1: mock-infected,
lanes 2^4: RSV infected for 30 min, lane 3: cells treated with 50 WM of AG490 prior to RSV infection, lane 4: cells treated with 25 WM of
PD98059 for 4 h prior RSV infection. B: The bands were quanti¢ed by densitometry and the relative intensity of phosphoSTAT-1K, phospho-
ERK and phospho-IUBK with respect to uninfected control (lane 1) was determined. The experiment was repeated twice and the result of a rep-
resentative experiment is shown. C: E¡ect of DN STAT-1K on ERK activation. A549 cells were co-transfected with RL-TK plasmid and either
the WT (pRc/CMV-STAT-1K) (lanes 3 and 4) or DN mutant (pRc/CMV-STAT-1K) (Y701F) (lanes 5 and 6) and were infected with RSV for
30 min after 24 h of transfection. Total proteins were extracted and Western-blotted using antibodies to phospho-STAT-1K, phospho-ERK-1/2
and reprobed with antibodies to STAT-1K or ERK-1/2. D: The bands were quanti¢ed by densitometry and the relative intensity of phospho-
ERK and ERK was determined in each band. The experiment was repeated twice and the result of a representative experiment is shown.
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indicate that ERK-1/2 pathway plays a role during the infec-
tion.
3.4. Requirement of STAT and ERK-1/2 activation for
successful RSV infection of primary NHBE cells
To determine if both JAK-STAT-1K and ERK pathways
are required for a successful RSV infection in primary NHBE
cells, they were exposed to either AG490 or PD98059 before
being infected with rgRSV. Exposure of NHBE to AG490 or
PD98059 caused a signi¢cant reduction in the number of in-
fected cells (Fig. 5). These results strongly suggest that JAK-
STAT-1K and ERK-1/2 are required for a successful RSV
infection in bronchial epithelial cells.
4. Discussion
This report provides evidence in support of a rapid and
transient activation of ERK-1/2 in RSV-infected A549 cells.
Such activation appears to be dependent on the presence of
phospho-STAT-1K and is required for both STAT-1K and
IUBK phosphorylation. Results of studies using DN mutants
and speci¢c inhibitors indicate that ERK-1/2 activation is im-
Fig. 4. Inhibition of ERK-1/2 activation decreases RSV infection of A549 cells. A: PD98059- or DMSO-treated A549 cells were infected with
RSV. Supernatants were collected from control and treated cells at 72 h. The RSV titers were determined using a HEP-2 cell-based plaque as-
say as described. B: Single cell immuno£uorescent assays of A549 cells co-transfected with RL-TK plasmid and either the WT (pCMV-HA
MEK) or DN mutant (pCMV-HA MEKm). Twenty-four hours after transfection, A549 cells were infected with RSV for 90 min and 24 h after
the % of infected cells was determined with FITC-RSV antibody.
Fig. 5. E¡ects of (insert) STAT and ERK-1/2 inhibitors on RSV infection of NHBE cells. NHBE cells were treated with either AG490 (50WM)
or PD98059 (80WM) for 2 h. DMSO was used as a mock control. After inhibitor removal, cells were infected with rgRSV for 2 h. Then, rgRSV
was removed and growth medium with inhibitors was added to the cells for 16 h before £uorescent images as well as light transmission images
were taken.
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portant for successful RSV infection. Also, ERK-1 and ERK-
2 activation constitutes an integral pathway of early signaling
cascades involved in RSV infection.
RSV was reported to activate ERK-2 at the early stages of
infection (10 min after RSV exposure) and that such activa-
tion was required for IL-8 production [22]. However, given
that RSV supernatant contains a number of cytokines and
chemokines which may activate ERK-2, the signi¢cance of
this report was unclear. In this study we con¢rm this report
by testing ERK activity in A549 cells exposed to sucrose-pu-
ri¢ed RSV, and present evidence of ERK-1 activation. The
rapid activation of ERK-1 and ERK-2 is consistent with our
previous ¢nding that a number of genes are activated within
30 min of RSV infection [16].
The rapid activation of ERK-1/2 after RSV infection led to
the hypothesis that RSV attachment causes ERK signaling,
which is supported by the fact that the heparin- or heparinase-
treated RSV did not induce ERK-1/2 phosphorylation. Both
RSV-G and -F proteins were reported to bind to heparan
sulfate on the cell surface [28^30]. Interestingly, however,
the treatment of A549 cells with heparinase, which abrogated
STAT-1K phosphorylation, did not a¡ect the phosphorylation
of ERK-1/2. The reason for the segregation of signaling in
heparinase-treated A549 cells after RSV exposure is unclear.
The fact that PD98059 and DN STAT-1K inhibited the
phosphorylation of STAT and ERK pathways, respectively,
suggests the existence of cross-talk between these pathways
during RSV infection. Previously, Stancato et al. have re-
ported that STAT-1 may sca¡old signaling components re-
quired for activation of the Raf/MEK/ERK signaling cascade
[31].
Notably, STAT-1K activation is also required for NF-UB
activation in infected cells evidenced by AG490 e¡ect upon
IUBK phosphorylation. This agrees with a previous report in
which the JAK inhibition prevented the degradation of IUBK
and blocked the translocation of NF-UB p65 into the nucleus
[32].
The evidence that inhibiting ERK signi¢cantly decreases
RSV infection in A549 and NHBE cells suggests that this
pathway may be important in turning on genes for virus rep-
lication and/or morphogenesis. To rule out the possibility that
this e¡ect on viral replication is due to diminished cell pro-
liferation, viable cells were enumerated at 12, 24, 48, and 72 h
after treatment with inhibitors. The results showed no signi¢-
cant di¡erence in cell numbers between treated and untreated
cells (data not shown).
Involvement of ERKs in virus infection is not unprece-
dented. ERK pathway activation is required at di¡erent levels
during HIV-1 infection. The association of ERK-2 with di¡er-
ent HIV-1 strains derived from T cells and promonocytic cells
has been reported [33]. ERK phosphorylates several HIV-1
proteins important for viral replication, such as Vif, Rev,
Tat, p17(Gag), and Nef [34]. HIV-1 infectivity is enhanced
when cells are treated with ERK stimulators or when cells
are transfected with activated forms of Ras, Raf, and MEK
molecules [34]. In addition, speci¢c inhibitors of the ERK
pathway such as PD98059 reduced the infectivity of HIV-1
virions [34]. Finally, HIV-1 infection of brain microvascular
endothelia is dependent on the activation of the ERK path-
way and inhibition of this pathway repressed virus entry [35].
In the same line, the ERK activation pathway is also re-
quired during the early stages of in£uenza infection. Inhibiting
the normal process that conveys the activation of ERK im-
pairs in£uenza virus replication because it a¡ects the early
stage of nuclear export of viral ribonucleoprotein, probably
as a result of impaired activity of the viral nuclear export
protein [36,37].
In addition to impairing viral infection, there are other in-
stances in which virus propagation could be a¡ected by block-
ing the function of the ERK pathway. In the case of Borna
disease virus, the ERK pathway seems to be required for the
virus to spread to neighboring cells [38]. Regarding viral
pathogenesis, ERK activation has been implicated in the de-
velopment of Visna virus infection-associated encephalitis,
and if this pathway is inhibited, viral replication is abolished
secondary to a defect in Rev function [39]. Present evidence
also indicates that hepatitis virus B, C, and E activate ERK
through di¡erent means and take advantage of such activa-
tion as a strategy for their own survival [40]. In the early
stages of infection, vaccinia virus triggers the activation of
ERK through an unknown mechanism. Interestingly, when
cells are exposed to inhibitors of the ERK pathway, the viral
multiplication is impaired [41].
Taken together, all of these previous reports highlight the
role the ERK pathway in the e⁄cient infection and replication
of certain virus species as well as how evolution has endowed
these viruses to develop mechanisms that allowed them to
sequester host cell signaling pathways. This report establishes
for the ¢rst time that STAT-1K, and ERK-1/2 are required for
successful RSV infection. The demonstration that RSV infec-
tion is inhibited in primary NHBE cells con¢rms the general-
ity of the signaling requirement seen in A549 cells.
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